Previous 10 | Next 10 |
Initial data from pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG) expected in June 2022 Company plans to initiate pivotal Phase 3 FIREFLY-2 clinical trial evaluating tovorafenib as a first-line therapy in pLGG in the second quarter of 20...
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that ma...
Day One Biopharmaceuticals press release (NASDAQ:DAWN): FY GAAP EPS of -$4.62 misses by $0.85. Cash and cash equivalents totaled $284.3 million on December 31, 2021. For further details see: Day One Biopharmaceuticals GAAP EPS of -$4.62 misses by $0.85
Initial data from pivotal FIREFLY-1 study with DAY101 (tovorafenib) expected in June 2022 Targeted enrollment achieved in pivotal FIREFLY-1 study Topline results from pivotal FIREFLY-1 study expected in Q1 2023 Current cash provides runway into 2024 and through multiple expect...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced manageme...
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr....
After a decline of more than 10% on Wednesday, Day One Biopharmaceuticals (DAWN +18.4%) is trading sharply higher to post the biggest intraday gain since its IPO in May. About 113.7K company shares have changed hands compared to the 65-day average volume of ~105.1K shares. The small-cap biote...
Gainers: Ardelyx ARDX +38%. Biofrontera BFRI +21%. Jowell Global (NASDAQ:JWEL) +19%. Duluth Holdings DLTH +17%. Day One Biopharmaceuticals (NASDAQ:DAWN) +17%. Losers: Tantech Holdings TANH -57%. Kirkland's KIRK -27%. Context Therapeutics...
Gainers: Biofrontera (NASDAQ:BFRI) +36%. CF Acquisition (NASDAQ:CFVIU) +19%. Day One (NASDAQ:DAWN) +16%. Terns Pharmaceuticals (NASDAQ:TERN) +15%. Duluth Holdings (NASDAQ:DLTH) +15%. Snowflake (NYSE:SNOW) +14%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +14%. Express (NYSE:EXPR) +13%. Vor Biopharm...
Phase 1b/2 Study Evaluating DAY101 in Combination with Pimasertib, Day One’s MEK Inhibitor, Expected to Begin in First Quarter of 2022 SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical ...
News, Short Squeeze, Breakout and More Instantly...
Day One Biopharmaceuticals Inc. Company Name:
DAWN Stock Symbol:
NASDAQ Market:
Day One Biopharmaceuticals Inc. Website:
2024-07-20 21:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-10 18:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 09:30:06 ET Piper Sandler analyst issues OVERWEIGHT recommendation for DAWN on July 8, 2024 07:54AM ET. The previous analyst recommendation was Overweight. DAWN was trading at $13.71 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...